- Home
- ADVM
as 07-26-2024 4:00pm EST
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 142.4M | IPO Year: | 2014 |
| Target Price: | $32.83 | AVG Volume (30 days): | 609.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.38 - $29.70 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -90.53% | Revenue Growth (next year): | 3585.71% |
Stock Insider Trading Activity of Adverum Biotechnologies Inc. (ADVM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ADVM | 10% Owner | Jul 18 '24 | Buy | $9.11 | 80,718 | $735,736.50 | 2,182,264 | SEC Form 4 |
| Leonard Braden Michael | ADVM | 10% Owner | Jul 18 '24 | Buy | $7.75 | 135,546 | $1,049,925.76 | 2,101,546 | SEC Form 4 |
| Lupher, Jr. Mark L. | ADVM | Director | Feb 7 '24 | Buy | $1.35 | 130,000 | $175,500.00 | 130,000 | SEC Form 4 |
| Scopa James Paul | ADVM | Director | Feb 7 '24 | Buy | $1.35 | 100,000 | $135,000.00 | 100,000 | SEC Form 4 |
Latest Adverum Biotechnologies Inc. News
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
MT Newswires
9 days ago
Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating
MT Newswires
10 days ago
Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug
GlobeNewswire
10 days ago
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Zacks
10 days ago
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
GlobeNewswire
17 days ago
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
MT Newswires
a month ago
Oppenheimer Initiates Coverage on Adverum Biotechnologies With Outperform Rating, $25 Price Target
GlobeNewswire
a month ago
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
Compare ADVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.